DOP2010000251A - Paramyxovirus eficaz como antitumoral - Google Patents
Paramyxovirus eficaz como antitumoralInfo
- Publication number
- DOP2010000251A DOP2010000251A DO2010000251A DO2010000251A DOP2010000251A DO P2010000251 A DOP2010000251 A DO P2010000251A DO 2010000251 A DO2010000251 A DO 2010000251A DO 2010000251 A DO2010000251 A DO 2010000251A DO P2010000251 A DOP2010000251 A DO P2010000251A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- virus
- paramyxovirus
- kill
- antitumoral
- effective
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241001559177 Mapuera rubulavirus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000531454 Reptilian ferlavirus Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapuera y virus Fer-de-Lance, los cuales pueden ser usados para la producción de un medicamento para eI tratamiento de tumores. El virus tiene una selectividad para matar células tumorales humanas pero no para matar células diferenciadas normales humanas o en proliferación normal humanas con la misma dosis. Por medio de ingeniería genética, el virus se puede modificar de modo tal que se agreguen o reemplacen uno o más genes por los genes homólogos de un paramyxovirus relacionado. Por ese método, la actividad antitumoral del virus quimérico resultante se potencia en comparación con el virus parental.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08075121 | 2008-02-14 | ||
| US2965008P | 2008-02-19 | 2008-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2010000251A true DOP2010000251A (es) | 2010-08-31 |
Family
ID=40955326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2010000251A DOP2010000251A (es) | 2008-02-14 | 2010-08-13 | Paramyxovirus eficaz como antitumoral |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090208495A1 (es) |
| EP (1) | EP2252307A2 (es) |
| JP (1) | JP2011512344A (es) |
| KR (1) | KR20100122482A (es) |
| CN (1) | CN101945660A (es) |
| AU (1) | AU2009214066A1 (es) |
| BR (1) | BRPI0908365A2 (es) |
| CA (1) | CA2715136A1 (es) |
| CO (1) | CO6290694A2 (es) |
| CR (1) | CR11631A (es) |
| DO (1) | DOP2010000251A (es) |
| EA (1) | EA201001266A1 (es) |
| EC (1) | ECSP10010401A (es) |
| IL (1) | IL206860A0 (es) |
| MX (1) | MX2010008942A (es) |
| WO (1) | WO2009101149A2 (es) |
| ZA (1) | ZA201006561B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE053237T2 (hu) * | 2009-08-21 | 2021-06-28 | Boehringer Ingelheim Animal Health Usa Inc | Rekombináns madárparamixovírus-vakcina és eljárás elõállítására és alkalmazására |
| GB0915515D0 (en) * | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
| EP2579884B1 (en) | 2010-06-10 | 2014-06-04 | Intervet International B.V. | Anti-tumor composition |
| ES2728248T3 (es) * | 2012-01-24 | 2019-10-23 | Univ Georgia | Vacunas basadas en el virus paragripal 5 |
| WO2015032755A1 (en) * | 2013-09-03 | 2015-03-12 | Medimmune Limited | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| US20200297787A1 (en) * | 2018-07-13 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| CN115089591B (zh) * | 2022-05-21 | 2024-04-12 | 复旦大学 | 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用 |
| CN116970650B (zh) * | 2023-09-22 | 2023-12-08 | 深圳华大生命科学研究院 | 一种包膜蛋白组合、含其的靶向病毒载体及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530301A (ja) * | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
| AU7607900A (en) * | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| BRPI0517834A (pt) * | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
-
2009
- 2009-02-10 US US12/368,330 patent/US20090208495A1/en not_active Abandoned
- 2009-02-12 CN CN2009801051826A patent/CN101945660A/zh active Pending
- 2009-02-12 AU AU2009214066A patent/AU2009214066A1/en not_active Abandoned
- 2009-02-12 KR KR1020107017980A patent/KR20100122482A/ko not_active Withdrawn
- 2009-02-12 CA CA2715136A patent/CA2715136A1/en not_active Abandoned
- 2009-02-12 WO PCT/EP2009/051659 patent/WO2009101149A2/en not_active Ceased
- 2009-02-12 MX MX2010008942A patent/MX2010008942A/es not_active Application Discontinuation
- 2009-02-12 BR BRPI0908365-0A patent/BRPI0908365A2/pt not_active IP Right Cessation
- 2009-02-12 EP EP09709608A patent/EP2252307A2/en not_active Withdrawn
- 2009-02-12 EA EA201001266A patent/EA201001266A1/ru unknown
- 2009-02-12 JP JP2010546341A patent/JP2011512344A/ja active Pending
-
2010
- 2010-07-07 IL IL206860A patent/IL206860A0/en unknown
- 2010-08-12 EC EC2010010401A patent/ECSP10010401A/es unknown
- 2010-08-13 CR CR11631A patent/CR11631A/es not_active Application Discontinuation
- 2010-08-13 CO CO10100021A patent/CO6290694A2/es not_active Application Discontinuation
- 2010-08-13 DO DO2010000251A patent/DOP2010000251A/es unknown
- 2010-09-13 ZA ZA2010/06561A patent/ZA201006561B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010008942A (es) | 2010-09-07 |
| IL206860A0 (en) | 2010-12-30 |
| CO6290694A2 (es) | 2011-06-20 |
| CR11631A (es) | 2010-10-05 |
| AU2009214066A1 (en) | 2009-08-20 |
| CN101945660A (zh) | 2011-01-12 |
| BRPI0908365A2 (pt) | 2015-08-11 |
| JP2011512344A (ja) | 2011-04-21 |
| WO2009101149A3 (en) | 2009-11-05 |
| US20090208495A1 (en) | 2009-08-20 |
| WO2009101149A2 (en) | 2009-08-20 |
| KR20100122482A (ko) | 2010-11-22 |
| ECSP10010401A (es) | 2010-09-30 |
| CA2715136A1 (en) | 2009-08-20 |
| EA201001266A1 (ru) | 2011-04-29 |
| EP2252307A2 (en) | 2010-11-24 |
| ZA201006561B (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CY1122275T1 (el) | Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2015007925A (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. | |
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| CU20140139A7 (es) | Compuestos y composiciones para modular la actividad de egfr | |
| MY168762A (en) | Certain chemical entities, compositions and methods | |
| MX2015010724A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| EA201590888A1 (ru) | Мутации флавивирусного белка оболочки, нарушающие разборку вириона | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| EA028928B9 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| EA201391492A1 (ru) | Соединения на основе микрорнк и способы модулирования активности mir-21 | |
| CU20120018A7 (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
| MX2013010557A (es) | Anticuerpo del factor tisular humano y usos de este. | |
| MX371275B (es) | Composiciones derivadas de la quitosana. | |
| UY34773A (es) | Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos | |
| MX2015012471A (es) | Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas. | |
| UY34420A (es) | ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos" | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| BR112015010225A2 (pt) | compostos tricíclicos e seus métodos de produção e utilização | |
| EA201590782A1 (ru) | Оксирановые амины | |
| GB2528604A (en) | Modulation of asymmetric proliferation |